Exelixis, Inc. (EXEL) Stock Price & Analysis
Exelixis, Inc. (EXEL) fell 0.50% to USD 55.37 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
EXEL last closed at USD 55.65; the session ranged USD 55.11–56.34 on volume of 1,143,950 shares. Market capitalization is $13.92B, with a 52-week range of USD 33.76–57.57 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 55.37 |
|---|---|
| Change | ▼ 0.50% (down) |
| Previous Close | USD 55.65 |
| Open | USD 56.07 |
| Day Range | USD 55.11 – 56.34 |
| 52-Week Range | USD 33.76 – 57.57 |
| Volume | 1,143,950 shares |
| Market Cap | $13.92B |
| Exchange | NMS |
Technical Analysis (EXEL)
Nexqual's technical model rates EXEL "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.36 (neutral) |
| vs SMA50 | Above (USD 53.05) |
| MACD | 0.8 (positive) |
Analyst Ratings (EXEL)
Wall Street analysts rate EXEL "Buy" based on 15 analysts, with a mean price target of USD 52.07 (range USD 41–64), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 52.07 |
| High Target | USD 64 |
| Low Target | USD 41 |
| Buy / Hold / Sell | 8 / 10 / 1 |
Earnings (EXEL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.86 |
| Revenue Estimate | $636.15M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.87 vs est 0.76 ▲ beat |
| 2025-12-31 | USD 0.94 vs est 0.81 ▲ beat |
| 2025-09-30 | USD 0.78 vs est 0.67 ▲ beat |
| 2025-06-30 | USD 0.75 vs est 0.65 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (EXEL)
| Total Revenue | $2.38B |
|---|---|
| Revenue Growth (YoY) | +10.00% |
| Gross Margin | +96.44% |
| Operating Margin | +41.15% |
| Profit Margin | +35.08% |
| ROE | +40.99% |
| Debt / Equity | 8.76 |
| Current Ratio | 3.26 |
| Total Cash | $777.21M |
| Total Debt | $169.54M |
| Free Cash Flow | $629.12M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (EXEL)
Nexqual rates Exelixis, Inc.'s overall financial health "Strong" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 41% |
| Balance Sheet | Strong — $777M cash vs $170M debt, net cash position |
| Cash Flow | Strong — FCF $629M, 27% margin |
| Efficiency | Strong — ROE 41%, ROA 22.0% |
Ownership (EXEL)
| Insider Ownership | +1.82% |
|---|---|
| Institutional Ownership | +106.69% |
| Shares Outstanding | 251.36M |
| Float | 204.45M |
| Short % of Float | +15.44% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (EXEL)
Exelixis, Inc. is led by Michael M. Morrissey (age 64), CEO, President & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO, President & Director | Michael M. Morrissey (age 64) |
|---|---|
| Executive VP & CFO | Christopher J. Senner (age 57) |
| Executive Vice President of Research & Development | Dana T. Aftab (age 61) |
| Executive Vice President of Commercial | Patrick Joseph Haley (age 49) |
| Senior Vice President of Medical Affairs | William Berg |
Major Backers & Investors (EXEL)
Notable institutional backers of Exelixis, Inc. include Renaissance Technologies, Farallon Capital Management LLC, AQR Capital Management, LLC, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 5.46% |
| Farallon Capital Management LLC | 5.22% |
| AQR Capital Management, LLC | 5.21% |
| Fuller & Thaler Asset Management Inc. | 3.4% |
| LSV Asset Management | 3.08% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.1% |
| BlackRock | 16.51% |
| State Street | 5.62% |
| Geode Capital | 3.1% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Exelixis, Inc.'s Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
- The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
- Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
- The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 117.67 | ▲ 1.62% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 59.33 | ▲ 1.59% |
| ACAD | ACADIA Pharmaceuticals Inc. | USD 24.84 | ▼ 0.48% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 477.36 | ▲ 1.01% |
| NBIX | Neurocrine Biosciences, Inc. | USD 175.77 | ▲ 1.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.